{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:37:12Z","timestamp":1787017032771,"version":"build-2736575974"},"reference-count":40,"publisher":"BMJ","issue":"2","funder":[{"name":"Ministry of Health & Welfare, Republic of Korea"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2018,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The onset of parkinsonism in patients with drug-induced parkinsonism (DIP) exhibits extensive individual variability following exposure to offending drugs. We investigated whether the individual variations in the onset time of parkinsonism reflected the underlying subtle dopaminergic dysfunction in DIP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We enrolled 71 patients with DIP who had visually normal striatal dopamine transporter (DAT) availability in\n                      <jats:sup>18<\/jats:sup>\n                      F-FP-CIT positron emission tomography scans. According to their exposure durations to the offending drugs prior to onset of the parkinsonism, the patients were divided into the early-onset group (duration \u22646 months; n=35) and delayed-onset group (duration &gt;6 months; n=36). We performed the quantitative analysis of the DAT availability in each striatal subregion between the groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No patients with DIP had DAT availability that was more than 2 SD below the normal mean of DAT availability. Compared with the delayed-onset group, the early-onset DIP group had decreased DAT availability in the striatal subregions including the posterior putamen (p=0.018), anterior putamen (p=0.011), caudate (p=0.035) and ventral striatum (p=0.027). After adjusting for age, sex and cross-cultural smell identification test scores, a multivariate analysis revealed that the DAT availability in the striatal subregions of the patients with DIP was significantly and positively associated with the natural logarithm of the duration of drug exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results suggest that a short exposure to the offending drugs before the development of parkinsonism would be associated with subtle nigrostriatal dopaminergic dysfunction in patients with DIP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2017-315873","type":"journal-article","created":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T20:50:17Z","timestamp":1505422217000},"page":"169-174","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Early-onset drug-induced parkinsonism after exposure to offenders implies nigrostriatal dopaminergic dysfunction"],"prefix":"10.1136","volume":"89","author":[{"given":"Seok Jong","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Soo","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyojeong","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungsu S","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Seung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Hee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Yong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Seok","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young H","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phil Hyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"2020050722285271000_89.2.169.1","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2012.8.1.15"},{"key":"2020050722285271000_89.2.169.2","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/mds.26209","article-title":"Parkinsonism following neuroleptic exposure: A double-hit hypothesis?","volume":"30","author":"Erro","year":"2015","journal-title":"Mov Disord"},{"key":"2020050722285271000_89.2.169.3","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10575"},{"key":"2020050722285271000_89.2.169.4","doi-asserted-by":"crossref","unstructured":"Hong JY , Sunwoo MK , Oh JS , et al . Persistent Drug-Induced Parkinsonism in Patients with Normal Dopamine Transporter Imaging. PLoS One 2016;11:e0157410.doi:10.1371\/journal.pone.0157410","DOI":"10.1371\/journal.pone.0157410"},{"key":"2020050722285271000_89.2.169.5","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20748"},{"key":"2020050722285271000_89.2.169.6","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.schres.2013.11.028","article-title":"Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study","volume":"152","author":"Tinazzi","year":"2014","journal-title":"Schizophr Res"},{"key":"2020050722285271000_89.2.169.7","doi-asserted-by":"publisher","DOI":"10.1017\/S003329170003960X"},{"key":"2020050722285271000_89.2.169.8","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800250087012"},{"key":"2020050722285271000_89.2.169.9","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23828"},{"key":"2020050722285271000_89.2.169.10","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/1353-8020(96)00013-2","article-title":"Drug-induced parkinsonism in a movement disorders unit: A four-year survey","volume":"2","author":"Jim\u00e9nez-Jim\u00e9nez","year":"1996","journal-title":"Parkinsonism Relat Disord"},{"key":"2020050722285271000_89.2.169.11","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.2.318"},{"key":"2020050722285271000_89.2.169.12","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1002\/mds.26418","article-title":"Is Dominant-Side Onset Associated With a Better Motor Compensation in Parkinson\u2019s Disease?","volume":"30","author":"Ham","year":"2015","journal-title":"Mov Disord"},{"key":"2020050722285271000_89.2.169.13","doi-asserted-by":"publisher","DOI":"10.1097\/00004647-200109000-00002"},{"key":"2020050722285271000_89.2.169.14","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/WNR.0000000000000247","article-title":"Cerebellum-specific 18F-FDG PET analysis for the detection of subregional glucose metabolism changes in spinocerebellar ataxia","volume":"25","author":"Oh","year":"2014","journal-title":"Neuroreport"},{"key":"2020050722285271000_89.2.169.15","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22098"},{"key":"2020050722285271000_89.2.169.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0322-9"},{"key":"2020050722285271000_89.2.169.17","doi-asserted-by":"publisher","DOI":"10.1211\/0022357021778358"},{"key":"2020050722285271000_89.2.169.18","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/00002826-199302000-00012","article-title":"An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia","volume":"16","author":"Gunne","year":"1993","journal-title":"Clin Neuropharmacol"},{"key":"2020050722285271000_89.2.169.19","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.neuropharm.2015.02.024","article-title":"Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism","volume":"95","author":"Cannella","year":"2015","journal-title":"Neuropharmacology"},{"key":"2020050722285271000_89.2.169.20","doi-asserted-by":"publisher","DOI":"10.1159\/000331768"},{"key":"2020050722285271000_89.2.169.21","first-page":"312","article-title":"A genetic dissection of antipsychotic induced movement disorders","volume":"20","author":"Crisafulli","year":"2013","journal-title":"Curr Med Chem"},{"key":"2020050722285271000_89.2.169.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2003.09.040"},{"key":"2020050722285271000_89.2.169.23","doi-asserted-by":"publisher","DOI":"10.1002\/syn.10177"},{"key":"2020050722285271000_89.2.169.24","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410330516"},{"key":"2020050722285271000_89.2.169.25","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0026-895X(25)09898-0","article-title":"Flunarizine and cinnarizine inhibit mitochondrial complexes I and II: possible implication for parkinsonism","volume":"45","author":"Veitch","year":"1994","journal-title":"Mol Pharmacol"},{"key":"2020050722285271000_89.2.169.26","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/mds.26467","article-title":"Neuroleptic-induced Parkinsonism: Clinicopathological study","volume":"31","author":"Shuaib","year":"2016","journal-title":"Mov Disord"},{"key":"2020050722285271000_89.2.169.27","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-007-0621-0"},{"key":"2020050722285271000_89.2.169.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(00)00023-2"},{"key":"2020050722285271000_89.2.169.29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10072-014-1945-8","article-title":"Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography","volume":"36","author":"Shin","year":"2015","journal-title":"Neurol Sci"},{"key":"2020050722285271000_89.2.169.30","first-page":"397","article-title":"Dopamine-acetylcholine-GABA neuronal linkages in the extrapyramidal and limbic systems","volume":"16","author":"McGeer","year":"1977","journal-title":"Adv Biochem Psychopharmacol"},{"key":"2020050722285271000_89.2.169.31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mds.25828","article-title":"Reversible dopamine transporter reduction in drug-induced Parkinsonism","volume":"29","author":"Cilia","year":"2014","journal-title":"Mov Disord"},{"key":"2020050722285271000_89.2.169.32","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s11940-009-0019-3","article-title":"Drug-induced parkinsonism","volume":"11","author":"Susatia","year":"2009","journal-title":"Curr Treat Options Neurol"},{"key":"2020050722285271000_89.2.169.33","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.51.6.850"},{"key":"2020050722285271000_89.2.169.34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.archger.2012.05.001","article-title":"Combined use of \u00b9\u00b2\u00b3I-metaiodobenzylguanidine (MIBG) scintigraphy and dopamine transporter (DAT) positron emission tomography (PET) predicts prognosis in drug-induced Parkinsonism (DIP): a 2-year follow-up study","volume":"56","author":"Kim","year":"2013","journal-title":"Arch Gerontol Geriatr"},{"key":"2020050722285271000_89.2.169.35","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/sleep\/26.5.507","article-title":"Increased muscle activity during rapid eye movement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson\u2019s disease, and controls","volume":"26","author":"Eisensehr","year":"2003","journal-title":"Sleep"},{"key":"2020050722285271000_89.2.169.36","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70152-1"},{"key":"2020050722285271000_89.2.169.37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0006-8993(92)91112-R","article-title":"Flunarizine induces a transient loss of tyrosine hydroxylase immunoreactivity in nigrostriatal neurons","volume":"590","author":"Takada","year":"1992","journal-title":"Brain Res"},{"key":"2020050722285271000_89.2.169.38","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00007"},{"key":"2020050722285271000_89.2.169.39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40263-016-0341-8","article-title":"Valproate-associated parkinsonism: a critical review of the literature","volume":"30","author":"Brugger","year":"2016","journal-title":"CNS Drugs"},{"key":"2020050722285271000_89.2.169.40","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0570-5"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2017-315873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:15:12Z","timestamp":1750864512000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2017-315873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,1,15]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/jnnp-2017-315873"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2017-315873","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]}}}